{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:15:56Z","timestamp":1784139356974,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1016\/j.eururo.2008.01.007","type":"journal-article","created":{"date-parts":[[2008,2,21]],"date-time":"2008-02-21T12:25:50Z","timestamp":1203596750000},"page":"1021-1028","source":"Crossref","is-referenced-by-count":116,"title":["Effective Treatment of Neurogenic Detrusor Dysfunction by Combined High-Dosed Antimuscarinics without Increased Side-Effects"],"prefix":"10.1016","volume":"53","author":[{"given":"Bastian","family":"Amend","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Hennenlotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Horstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnulf","family":"Stenzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Dietrich","family":"Sievert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2008.01.007_bib1","series-title":"Incontinence","author":"Abrams","year":"2005"},{"key":"10.1016\/j.eururo.2008.01.007_bib2","first-page":"703","article-title":"Guidelines on neurogenic lower urinary tract dysfunction","volume":"17","author":"Stohrer","year":"2007","journal-title":"Prog Urol"},{"key":"10.1016\/j.eururo.2008.01.007_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/(SICI)1520-6777(1999)18:2<139::AID-NAU9>3.0.CO;2-U","article-title":"The standardization of terminology in neurogenic lower urinary tract dysfunction: with suggestions for diagnostic procedures. International Continence Society Standardization Committee","volume":"18","author":"Stohrer","year":"1999","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2008.01.007_bib4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/01.phm.0000219229.92056.c2","article-title":"Pharmacotherapy for neurogenic detrusor overactivity","volume":"85","author":"Chancellor","year":"2006","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.eururo.2008.01.007_bib5","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00120-006-1096-5","article-title":"Oral anticholinergics in overactive bladder","volume":"45","author":"Madersbacher","year":"2006","journal-title":"Urologe A"},{"key":"10.1016\/j.eururo.2008.01.007_bib6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/(SICI)1520-6777(1998)17:5<499::AID-NAU6>3.0.CO;2-8","article-title":"Dose-ranging study of tolterodine in patients with detrusor hyperreflexia","volume":"17","author":"Van Kerrebroeck","year":"1998","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2008.01.007_bib7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2008.01.007_bib8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3949\/ccjm.69.10.761","article-title":"The newer antimuscarinic drugs: bladder control with less dry mouth","volume":"69","author":"Appell","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.eururo.2008.01.007_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/nau.20289","article-title":"Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage","volume":"25","author":"Horstmann","year":"2006","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2008.01.007_bib10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2008.01.007_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.amjmed.2005.12.011","article-title":"Using anticholinergics to treat overactive bladder: the issue of treatment tolerability","volume":"119","author":"Staskin","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.eururo.2008.01.007_bib12","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1111\/j.1464-410X.2006.06146.x","article-title":"Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia","volume":"97","author":"Nitti","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2008.01.007_bib13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.eururo.2006.03.016","article-title":"Propiverine compared to oxybutynin in neurogenic detrusor overactivity\u2014results of a randomized, double-blind, multicenter clinical study","volume":"51","author":"St\u00f6hrer","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.01.007_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1159\/000282207","article-title":"Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial","volume":"47","author":"Stohrer","year":"1991","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2008.01.007_bib15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.5414\/CPP40295","article-title":"Trospium chloride in patients with detrusor overactivity: meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20mg trospium chloride twice daily","volume":"40","author":"Frohlich","year":"2002","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.eururo.2008.01.007_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0090-4295(97)00599-2","article-title":"Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis","volume":"50","author":"Appell","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2008.01.007_bib17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.5414\/CPP44623","article-title":"Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients?","volume":"44","author":"Menarini","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.eururo.2008.01.007_bib18","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2006.07.017","article-title":"Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review","volume":"50","author":"Novara","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.01.007_bib19","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.eururo.2006.07.018","article-title":"Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: where do we stand in 2006?","volume":"50","author":"Irani","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.01.007_bib20","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2008.01.007_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00019052-200404000-00007","article-title":"Rodent models for treatment of spinal cord injury: research trends and progress toward useful repair","volume":"17","author":"Rosenzweig","year":"2004","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.eururo.2008.01.007_bib22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0090-4295(02)01803-4","article-title":"Muscarinic receptor subtypes and management of the overactive bladder","volume":"60","author":"Chapple","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2008.01.007_bib23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","article-title":"Antimuscarinics for treatment of overactive bladder","volume":"3","author":"Andersson","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.eururo.2008.01.007_bib24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00120-007-1326-5","article-title":"How do medications used to treat urinary incontinence affect the cerebral function of the elderly?","volume":"46","author":"Goepel","year":"2007","journal-title":"Urologe A"},{"key":"10.1016\/j.eururo.2008.01.007_bib25","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1464-410X.1995.tb07264.x","article-title":"Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia","volume":"75","author":"Madersbacher","year":"1995","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2008.01.007_bib26","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","article-title":"Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability","volume":"20","author":"Halaska","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2008.01.007_bib27","first-page":"2061","article-title":"Newer agents for the management of overactive bladder","volume":"74","author":"Epstein","year":"2006","journal-title":"Am Fam Physician"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2008.01.007_bib28","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1038\/sj.bjp.0706560","article-title":"Muscarinic receptors in the bladder: from basic research to therapeutics","volume":"147","author":"Hegde","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.eururo.2008.01.007_bib29","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/00912700122010528","article-title":"Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system","volume":"41","author":"Todorova","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.eururo.2008.01.007_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.eururo.2006.03.060","article-title":"Antimuscarinics and cognitive function","volume":"50","author":"Ridder","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.01.007_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2006.03.057","article-title":"Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects","volume":"50","author":"Kay","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.01.007_bib32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1464-410X.2006.06192.x","article-title":"Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury","volume":"98","author":"Patki","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2008.01.007_bib33","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1590\/S1677-55382006000600002","article-title":"The challenge of overactive bladder therapy: alternative to antimuscarinic agents","volume":"32","author":"Lazzeri","year":"2006","journal-title":"Int Braz J Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283808000079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283808000079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T04:33:03Z","timestamp":1588393983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283808000079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["S0302283808000079"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2008.01.007","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}